Vertex has reached a key moment because the U.S. Food and Drug Administration (FDA) is reviewing its candidate, suzetrigine, ...

These are the 300 companies whose success goes beyond profits to include employee and customer sentiment, cybersecurity, ...

Both stocks have made significant breakthroughs. Among the qualities a biotech company needs to be successful, being innovative is one of the most important. It's easy to understand why. Although ...

We are thrilled to announce that Recursion is setting a new gold standard for the industry with the release of ...

Dealmaking this year has been largely muted, but M&A trends are pointing to the areas where pharma is placing the most ...

Wang covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Alnylam Pharma, and Vertex Pharmaceuticals ... development and commercialization of human therapeutic drugs using ...

Research and development expense was $15.5 million for the third quarter of 2024, as compared to $7.6 million for the prior ...

Meta stock and Nvidia peer Broadcom are among among five S&P 500 stocks on IBD Leaderboard that are near buy points.

Neurocrine Biosciences, Inc.'s potential for growth in the biopharma sector is strong despite recent setbacks, making its ...

Royalty Pharma's Q3 results show growth driven by strong portfolio performance and acquisitions. See why we recommend a buy ...

Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...

These three emerging technology leaders are pioneering quantum computing, gene editing, and electric aviation.